Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN DEXTROSE 5 IN PLASTIC CONTAINER versus AMINOSYN II 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN DEXTROSE 5 IN PLASTIC CONTAINER versus AMINOSYN II 8 5 W ELECTROLYTES.
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER vs AMINOSYN II 8.5% W/ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminogen II 3.5% M in Dextrose 5% provides essential and non-essential amino acids and dextrose for parenteral nutrition. Amino acids are utilized for protein synthesis and metabolic processes. Dextrose provides a source of calories and energy.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Aminosin II 3.5% M in Dextrose 5% is administered intravenously. Typical adult dose is 1-2 L per day, providing 35-70 g amino acids and 50-100 g dextrose per day, infused at a rate of 0.5-1.5 mL/kg/hour.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
None Documented
None Documented
Amino acids have variable elimination half-lives (e.g., 0.5-6 h) depending on individual amino acid; dextrose half-life ~1-2 h. Clinical context: Used for continuous infusion, not bolus.
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Amino acids are primarily metabolized, with nitrogen excreted as urea (renal, ~80-90%) and ammonia; minimal fecal excretion. Dextrose is fully metabolized to CO2 and water.
Renal >90% (as amino acids and metabolites); fecal <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution